S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial

Overview of attention for article published in BMC Cancer, November 2014

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Above-average Attention Score compared to outputs of the same age and source (53rd percentile)

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 32 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 35,306 followers.

@goat_invest 私もそう思うんですが、ビビリなのでゼローダからS-1に変更できる/できないがん種やステージは？とか、変更後の治療成績は？とかが気になってしまってます😞 レジメン多すぎて途方もないですね💦 進行大腸がんについてはこんな報告がありました↓ https://t.co/rkgAzhdS3l

09 Nov 2021

Reply Repost Favourite

S-1 w/ oxaliplatin vs. capecitabine w/ oxaliplatin for treatment of patients with metastatic colorectal cancer.http://t.co/sVDgStSo5d

05 Sep 2015

Reply Repost Favourite

転移再発大腸がん1次治療におけるSOXのCapeOXに対する非劣性（というか微妙に勝ちそう）。OS HR 0.86 (0.68-1.08)。／BMC Cancer http://t.co/o9vOztKCuZ http://t.co/0D2mEAk12y

03 Dec 2014

Reply Repost Favourite